Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Ironwood ends gout drug deal with AZ

August 10, 2018 4:28 PM UTC

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) terminated its deal with AstraZeneca plc (LSE:AZN; NYSE:AZN) for rights to the pharma's gout drugs Zurampic lesinurad and Duzallo lesinurad/allopurinol.

Ironwood said franchise test markets of the drugs did not meet expectations. The biotech recorded $1.1 million in combined 2Q18 sales of Zurampic and Duzallo. Together the drugs generated sales of $3.1 million in 2017...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article